Form 4: Bioventus CEO Claypoole's Equity Transactions
Insider Transaction Report
Bioventus Inc. CEO Robert E. Claypoole reported significant equity transactions, including RSU vesting, option grants, and stock acquisitions and dispositions.
Summary
- Robert E. Claypoole, President and CEO of Bioventus Inc., reported several equity transactions.
- Acquired 33,500 shares of Class A Common Stock on March 13, 2026, through the vesting of restricted stock units.
- Disposed of 14,553 shares of Class A Common Stock on March 13, 2026, at a price of $8.62 per share, likely for tax withholding purposes related to the RSU vesting.
- Beneficial ownership of Class A Common Stock following these transactions is 135,944 shares.
- Received new grants of 134,000 Restricted Stock Units and 153,000 Stock Options (with an exercise price of $9.61) on March 14, 2025.
- Received additional new grants of 278,000 Restricted Stock Units and 309,000 Stock Options (with an exercise price of $8.62) on March 13, 2026.
- The Restricted Stock Units and Stock Options granted on March 14, 2025, are scheduled to vest in four equal annual installments, commencing on March 15, 2025.
- The Restricted Stock Units and Stock Options granted on March 13, 2026, are scheduled to vest in four equal annual installments, commencing on March 15, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine insider transaction report detailing executive compensation and tax-related stock movements, which typically has a neutral impact on market sentiment.
Positives
- Significant new equity grants, including 412,000 Restricted Stock Units and 462,000 Stock Options, align the CEO's long-term financial interests with shareholder value creation.
- The vesting schedule for these grants incentivizes sustained performance and continued service to the company over several years.
Negatives
- Disposition of 14,553 shares of Class A Common Stock, although likely for tax withholding, represents a reduction in direct share ownership.
Future Outlook
The vesting schedules for the newly granted Restricted Stock Units and Stock Options extend through March 2029 (for 2025 grants) and March 2030 (for 2026 grants), indicating a long-term incentive structure for the CEO tied to the company's future performance and the CEO's continued service.
Industry Context
StockSavvy.ai notes that these transactions represent routine executive compensation and insider reporting, common across publicly traded companies. The grants of equity-based incentives are a standard practice to align management's interests with long-term shareholder value.
Stakeholder Impact
- Shareholders: The equity grants align the CEO's long-term financial interests with the company's performance, potentially fostering greater commitment to shareholder value creation.
- Employees: Reflects standard executive compensation practices within the company.
Next Steps
- Continued vesting of Restricted Stock Units and Stock Options on their respective anniversary dates, subject to the reporting person's continued service.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of earliest transaction; grant of 134,000 Restricted Stock Units and 153,000 Stock Options. |
| 03/15/2025 | First vesting anniversary for the Restricted Stock Units and Stock Options granted on March 14, 2025. |
| 03/13/2026 | Transaction date for the vesting of 33,500 Restricted Stock Units, acquisition of 33,500 Class A Common Stock, disposition of 14,553 Class A Common Stock for tax, and grant of 278,000 Restricted Stock Units and 309,000 Stock Options. |
| 03/15/2026 | First vesting anniversary for the Restricted Stock Units and Stock Options granted on March 13, 2026. |
| 03/17/2026 | Signature date of the Form 4 filing. |
| 03/14/2035 | Expiration date for the Stock Options granted on March 14, 2025. |
| 03/13/2036 | Expiration date for the Stock Options granted on March 13, 2026. |
Keywords
Bioventus, BVS, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, CEO, Equity Compensation, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.